Table 2 Immunohistochemical parameters for basal-like and non-basal-like triple negative tumors
Non basal-like (n = 16) | Basal-like (n = 88) | |
|---|---|---|
KI67 | ||
<14 % | 12 (75.0) | 12 (13.6) |
14–19 % | 4 (4.5) | |
≥20 % | 4 (25.0) | 72 (81.8) |
CK5-6/EGFR/VIM (Basal phenotype) | ||
Negative | 16 (100.0) | |
Positive | 88 (100.0) | |
ALDH1 | ||
Negative | 16 (100.0) | 74 (84.1) |
Positive | 14 (15.9) | |
Cd24_pos | ||
Negative | 8 (50.0) | 57 (64.8) |
Positive | 8 (50.0) | 31 (35.2) |
CD44 | ||
Negative | 10 (62.5) | 25 (28.4) |
Positive | 6 (37.5) | 62 (70.5) |
Not specified | 1 (1.1) | |
CD24 and CD44 (Claudin phenotype) | ||
CD24−/CD44+ | 3 (18.8) | 40 (45.5) |
CD24+/CD44− | 5 (31.3) | 9 (10.2) |
Other associations | 8 (50.0) | 38 (43.2) |
Not specified | 1 (1.1) | |
E-Cadherine | ||
Negative | 5 (31.3) | 1 (1.1) |
Positive | 11 (68.8) | 87 (98.9) |
TRIO phenotype | ||
Negative | 4 (25.0) | 53 (60.2) |
Positive | 12 (75.0) | 34 (38.6) |
Not specified | 1 (1.1) | |
BCL2 phenotype | ||
Negative | 13 (81.3) | 79 (89.8) |
Positive | 2 (12.5) | 8 (9.1) |
Not specified | 1 (6.3) | 1 (1.1) |